V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 240000841 | 240000841 | null | null | null | null | 2017-06-30 | Methotrexate intrathecal | null | null | AML19 TRIAL | 101868035 |
| 240000842 | 240000842 | 1.88 | 104.1 | 03 | null | 2018-08-20 | Hydroxycarbamide | N | N | CHOP R | 100426689 |
| 240000844 | 240000844 | 1.86 | 75 | 03 | 2019-08-30 | 2019-09-16 | Hydroxycarbamide | 2 | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 101296655 |
| 240000858 | 240000858 | 1.66 | 57.2 | Adjuvant (A) | null | 2019-08-20 | null | 02 | Y | AML MYECHILD 01 IT CYT | 100601992 |
| 240000865 | 240000865 | 1.82 | 53.2 | 03 | 2017-03-31 | 2017-04-01 | null | 02 | N | DA | 100266902 |
| 240000875 | 240000875 | null | 102.9 | Curative (C) | 2016-06-07 | 2016-06-07 | AML 18 TRIAL | null | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 100634206 |
| 240000877 | 240000877 | 0 | null | Palliative (P) | null | 2017-12-22 | Hydroxycarbamide | 01 | N | AML19 TRIAL | 100225439 |
| 240000883 | 240000883 | 1.76 | 99.8 | Curative (C) | null | 2019-03-03 | Methotrexate intrathecal | N | N | CYTARABINE | 101154791 |
| 240000885 | 240000885 | null | null | null | null | 2019-05-07 | null | null | null | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 100992916 |
| 240000889 | 240000889 | 1.8 | 56.7 | Curative (C) | null | 2017-06-03 | CHOP R - 21 days | 02 | N | AML MYECHILD 01 IT CYT | 101245590 |
| 240000896 | 240000896 | 1.61 | 98.2 | Curative (C) | 2018-06-18 | 2018-06-20 | Hydroxycarbamide | N | Y | AML19 TRIAL | 101801479 |
| 240000897 | 240000897 | null | null | null | null | 2018-10-10 | Azacitidine | null | null | NOT MATCHED | 101338421 |
| 240000913 | 240000913 | null | null | null | null | 2018-03-18 | Trial Unspecified | null | null | METHOTREXATE | 100663161 |
| 240000917 | 240000917 | 1.79 | 47.6 | Curative (C) | null | 2018-10-28 | null | 02 | Y | TRETINOIN | 100682712 |
| 240000924 | 240000924 | 1.45 | 62.9 | Curative (C) | null | 2019-03-30 | CHOP R | 02 | N | AML19 TRIAL | 100096854 |
| 240000933 | 240000933 | null | null | null | null | 2019-08-17 | null | null | null | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 100910263 |
| 240000946 | 240000946 | null | null | null | 2020-01-09 | 2020-01-09 | AML 18 TRIAL | N | null | CYCLOPHOSPHAMIDE + CYTARABINE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 101205221 |
| 240000948 | 240000948 | 1.71 | 72.3 | Palliative (P) | 2018-03-15 | 2018-03-15 | null | 02 | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 101636865 |
| 240000960 | 240000960 | 1.81 | 78.15 | Curative (C) | 2017-04-29 | 2017-04-29 | AML 18 TRIAL | 02 | Y | AZACITIDINE | 101321769 |
| 240000963 | 240000963 | null | null | null | null | 2016-03-15 | AML 18 TRIAL | null | null | CYTARABINE | 101054177 |
| 240000964 | 240000964 | null | null | null | null | 2019-01-22 | null | null | null | CHOP R | 100239949 |
| 240000970 | 240000970 | null | null | null | null | 2018-11-17 | AML 19 TRIAL | null | null | HYDROXYCARBAMIDE | 100916897 |
| 240000974 | 240000974 | null | null | null | null | 2016-07-19 | DA | null | null | CYTARABINE + DAUNORUBICIN | 101398636 |
| 240000984 | 240000984 | 1.54 | 93.4 | Curative (C) | null | 2018-09-16 | null | 02 | N | CYCLOPHOSPHAMIDE + CYTARABINE + DOXORUBICIN + METHOTREXATE + RITUXIMAB + VINCRISTINE | 101342003 |
| 240001001 | 240001001 | 0 | 0 | Curative (C) | null | 2016-08-06 | null | N | N | FCR | 101519572 |
| 240001007 | 240001007 | 1.75 | 88 | Palliative (P) | null | 2018-03-15 | null | 02 | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE | 100213169 |
| 240001010 | 240001010 | 0 | 13.4 | Adjuvant (A) | null | 2019-10-17 | CLADRIBINE | N | N | AZACITIDINE | 101792012 |
| 240001011 | 240001011 | null | null | null | 2019-07-15 | 2019-07-16 | null | 02 | null | AML MYECHILD 01 IT CYT | 101383921 |
| 240001013 | 240001013 | null | null | null | null | 2019-01-06 | Hydroxycarbamide | null | null | AML19 TRIAL | 100155509 |
| 240001014 | 240001014 | 1.66 | 0 | Palliative (P) | null | 2016-12-01 | null | 01 | N | CYTARABINE + DAUNORUBICIN | 100181314 |
| 240001020 | 240001020 | null | null | null | null | 2017-11-01 | null | null | null | AML19 TRIAL | 101437343 |
| 240001025 | 240001025 | null | null | null | null | 2016-09-20 | null | null | null | CHOP R | 101612057 |
| 240001026 | 240001026 | 1.73 | 82.2 | Curative (C) | 2017-11-21 | 2017-11-25 | Cladribine (subcut) 5 days | N | N | HYDROXYCARBAMIDE | 100951996 |
| 240001027 | 240001027 | null | null | null | null | 2016-08-26 | AML 19 TRIAL | null | null | IMATINIB | 101152642 |
| 240001029 | 240001029 | null | null | null | null | 2019-11-28 | LIPOSOMAL DAUNORUBICIN + CYTARABINE (Vyxeos) | null | null | CYTARABINE + DAUNORUBICIN | 101660134 |
| 240001039 | 240001039 | null | null | null | null | 2016-08-04 | null | null | null | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 101520818 |
| 240001041 | 240001041 | 1.58 | 62 | Curative (C) | null | 2018-06-01 | null | N | null | AML MYECHILD 01 IT CYT | 101404433 |
| 240001043 | 240001043 | 1.63 | 94.8 | Curative (C) | 2019-02-26 | 2019-02-27 | Azacitidine | 02 | N | AZACITIDINE | 100262699 |
| 240001045 | 240001045 | 1.77 | 89.6 | Curative (C) | null | 2019-08-15 | null | 02 | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 100401691 |
| 240001049 | 240001049 | 1.88 | 92 | Curative (C) | null | 2019-10-30 | null | 02 | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 100906822 |
| 240001061 | 240001061 | null | null | null | null | 2018-05-17 | null | null | null | AML19 TRIAL | 100107348 |
| 240001074 | 240001074 | 1.88 | null | Palliative (P) | null | 2019-05-09 | Methotrexate intrathecal | 02 | N | HYDROXYCARBAMIDE | 100739475 |
| 240001076 | 240001076 | null | null | null | null | 2017-10-06 | null | null | null | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 101595100 |
| 240001078 | 240001078 | 1.77 | 102.9 | null | 2019-11-02 | 2019-11-03 | null | N | N | CABOZANTINIB | 101535892 |
| 240001083 | 240001083 | null | null | null | null | 2017-05-26 | Trial Unspecified | null | null | GEMTUZUMAB OZOGAMICIN | 100277792 |
| 240001091 | 240001091 | 1.8 | 16.6 | Curative (C) | null | 2018-08-01 | LIPOSOMAL DAUNORUBICIN + CYTARABINE (Vyxeos) | N | Y | AML19 TRIAL | 100020934 |
| 240001097 | 240001097 | null | null | null | 2018-11-14 | 2018-11-14 | null | 02 | null | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 101640739 |
| 240001098 | 240001098 | 1.55 | 63.2 | Palliative (P) | null | 2016-04-05 | null | N | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 100777210 |
| 240001103 | 240001103 | 1.7 | 31.4 | Disease modification (D) | null | 2018-04-05 | Methotrexate intrathecal | 02 | N | ALEMTUZUMAB | 101379720 |
| 240001112 | 240001112 | 1.83 | 61.7 | Curative (C) | 2018-09-22 | 2018-09-29 | Azacitidine | 02 | N | TRIPLE INTRATHECAL | 100383778 |